- Home
- MGNX vs WETO Comparison
MGNX vs WETO Comparison
Compare MGNX & WETO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- WETO
- Stock Information
- Founded
- MGNX 2000
- WETO 2019
- Country
- MGNX United States
- WETO China
- Employees
- MGNX N/A
- WETO N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- WETO
- Sector
- MGNX Health Care
- WETO
- Exchange
- MGNX Nasdaq
- WETO NYSE
- Market Cap
- MGNX 97.2M
- WETO 88.0M
- IPO Year
- MGNX 2013
- WETO 2025
- Fundamental
- Price
- MGNX $1.36
- WETO $2.90
- Analyst Decision
- MGNX Hold
- WETO
- Analyst Count
- MGNX 9
- WETO 0
- Target Price
- MGNX $5.33
- WETO N/A
- AVG Volume (30 Days)
- MGNX 378.7K
- WETO 1.4M
- Earning Date
- MGNX 05-13-2025
- WETO 01-01-0001
- Dividend Yield
- MGNX N/A
- WETO N/A
- EPS Growth
- MGNX N/A
- WETO N/A
- EPS
- MGNX N/A
- WETO N/A
- Revenue
- MGNX $154,050,000.00
- WETO $5,350,773.00
- Revenue This Year
- MGNX N/A
- WETO N/A
- Revenue Next Year
- MGNX $45.52
- WETO N/A
- P/E Ratio
- MGNX N/A
- WETO N/A
- Revenue Growth
- MGNX 255.31
- WETO N/A
- 52 Week Low
- MGNX $0.99
- WETO $1.50
- 52 Week High
- MGNX $5.77
- WETO $4.30
- Technical
- Relative Strength Index (RSI)
- MGNX 39.88
- WETO N/A
- Support Level
- MGNX $1.44
- WETO N/A
- Resistance Level
- MGNX $1.58
- WETO N/A
- Average True Range (ATR)
- MGNX 0.11
- WETO 0.00
- MACD
- MGNX -0.02
- WETO 0.00
- Stochastic Oscillator
- MGNX 17.65
- WETO 0.00
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About WETO WEBUS INTERNATIONAL LIMITED
Webus International Ltd operates on a business model of Mobility-as-a-Service to identify and solve inefficiencies associated with inflexible or low-quality public transportation and provide cost-efficient and customized mass transportation services under different scenarios with comprehensive digital platforms. It offers commute shuttle service, customized chartered bus service, packaged tour service and other service to customers.